Cancer and Venous Thromboembolism: Scope of the Problem

Donati M.B. . Cancer and thrombosis. Haemostasis. 1994; 4: 128–131.

Arkel Y.S. . Thrombosis and cancer. Semin Oncol. 2000; 4: 362–374.

Heit J.A. , O'Fallon W.M. , Petterson T.M. . Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 4: 1245–1248.

Heit J.A. , Silverstein M.D. , Mohr D.N. . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 4: 809–815.

Levitan N. , Dowlati A. , Remick S.C. . Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine. 1999; 4: 285–291.

Sorensen H.T. , Mellemkjaer L. , Nielsen G.L. . Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 4: 1846–1850.

Geerts W.H. , Pineo G.F. , Heit J.A. . Prevention of venous thromboembolism. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 4(3 suppl): 338S–400S.

Buller H.R. , Agnelli G. , Hull R. . Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 4(3 suppl): 401S–428S.

Lee A.Y. . Cancer and thrombolic disease: pathogenic mechanisms. Cancer Treat Rev. 2002; 4: 137–140.

Green K.B. , Silverstein R.L. . Hypercoagulability in cancer. HematolOncol Clin North Am. 1996; 4: 499–530.

Gale A.J. , Gordon S.G. . Update on tumor cell procoagulant factors. Acta Haematol. 2001; 4: 25–32.

Lee A.Y. , Julian J.A. , Levine M.N. . Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med. 1999; 4: 417–423.

Bick R.L. . Cancer-associated thrombosis. N Engl J Med. 2003; 4: 109–110.

Folkman J. . Tumor angiogenesis and tissue factor [comment]. Nat Med. 1996; 4: 167–168.

Fernandez P.M. , Rickles F.R. . Tissue factor and angiogenesis in cancer. Curr Opin Hematol. 2002; 4: 401–406.

Hejna M. , Raderer M. , Zielinski C.C. . Inhibition of metastases by anticoagulants. J Natl Cancer Inst. 1999; 4: 22–36.

Gordon S.G. , Cross B.A. . A factor X-activating cysteine protease from malignant tissue. J Clin Invest. 1981; 4: 1665–1671.

Falanga A. , Consonni R. , Marchetti M. . Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelo-cytic leukemia cells. Blood. 1998; 4: 143–151.

Korte W. . Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures. Clin Chem Lab Med. 2000; 4: 679–692.

Silverstein M.D. , Heit J.A. , Mohr D.N. . Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 4: 585–593.

Heit J.A. , Mohr D.N. , Silverstein M.D. . Predictors of recurrence after deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2000; 4: 761–768.

Heit J.A. , Silverstein M.D. , Mohr D.N. . Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 1999; 4: 445–453.

Mohr D.N. , Silverstein M.D. , Heit J.A. . The venous stasis syndrome after deep venous thromboembolism or pulmonary embolism: a population-based study. Mayo Clin Proc. 2000; 4: 1249–1256.

White R.H. , Zhou H. , Romano P.S. . Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003; 4: 446–455.

Kroegel C. , Reissig A. . Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration. 2003; 4: 7–30.

Walshe L.J. , Malak S.F. , Eagan J. . Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol. 2002; 4: 3276–3281.

Bern M.M. , Lokich J.J. , Wallach S.R. . Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med. 1990; 4: 423–428.

Couban S. , Goodyear M. , Burnell M. . A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. Blood. 2002; 4(suppl): 703a. Abstract

Heaton D.C. , Han D.Y. , Inder A. . Minidose (1 mg) warfarin as prophylaxis for central venous catheter thrombosis. Intern Med. 2002; 4: 84–88.

Monreal M. , Alastrue A. , Rull M. . Upper extremity deep venous thrombosis in cancer patients with venous access devices: prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost. 1996; 4: 251–253.

Reichardt P. , Kretzschmar A. , Biakhov M. . A phase III randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, Fragmin) in preventing catheter-related complications in cancer patients with central venous catheters. Proc Annu Meet Am Soc Clin Oncol. 2002; 4: 1474. Abstract.

Sallah S. , Wan J.Y. , Nguyen N.P. . Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002; 4: 575–579.

Thodiyil P.A. , Kakkar A.K. . Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002; 4: 1076–1077.

Heit J.A. , Petterson T.M. , Bailey K.R. . The influence of tumor site on venous thromboembolism risk among cancer patients: a population-based study. Blood. 2004; 4: 711a. Abstract 2596.

Quevedo J.F. , Buckner J.C. , Schmidt J.L. . Thromboembolism in patients with high-grade glioma. Mayo Clin Proc. 1994; 4: 329–332.

Kucek O. , Kwaan H.C. , Gunnak W. . Thromboembolic complications associated with L-asparaginase therapy. Cancer. 1985; 4: 702.

Liebman H.A. , Wada J.K. , Patch M.J. . Depression of functional and antigenic plasma antithrombin III due to therapy with L-asparaginase. Cancer. 1982; 4: 451–456.

Fisher B. , Costantino J. , Redmond C. . A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 4: 479–484.

Pritchard K.I. , Paterson A.H. , Paul N.A. . Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996; 4: 2731–2737.

Wun T. , Law L. , Harvey D. . Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 2003; 4: 1514–1520.

Kanne J.P. , Lanlani T.A. . Role of computed tomography and magnetic resonance imaging for deep venous thrombosis and pulmonary embolism. Circulation 2004; 4(12 suppl 1): I15–I21.

Gomes M.P. , Deitcher S.R. . Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Huntingt). 2003; 4: 126–135, 139.

Rees H. , Ang L.C. . Massive pulmonary tumor emboli in a sarcoma: an unusual cause of sudden death. Am J Forensic Med Pathol. 1996; 4: 146–150.

Siragusa S. . Plasma D-dimer test accuracy can be affected by heparin administration. Arch Intern Med. 2003; 4: 246.

Bates S.M. , Kearon C. , Crowther M. . A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. Ann Intern Med. 2003; 4: 787–794.

Owings J.T. , Gosselin R.C. , Battistella F.D. . Whole blood D-dimer assay: an effective noninvasive method to rule out pulmonary embolism. J Trauma. 2000; 4: 795–799.

Raimondi P. , Bongard O. , de Moerloose P. . D-dimer plasma concentration in various clinical conditions: implication for the use of this test in the diagnostic approach of venous thromboembolism. Thromb Res. 1993; 4: 125–130.

ten Wolde M. , Kraaijenhagen R.A. , Prins M.H. . The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis. Arch Intern Med. 2002; 4: 1880–1884.

Lee A.Y. . Screening for occult cancer in patients with idiopathic venous thromboembolism. J Thromb Haemost. 2003; 4: 2273–2274.

Piccioli A. , Prandoni P. . Screening for occult cancer inpatients with idiopathic venous thromboembolism. J Thromb Haemost. 2003; 4: 2271–2272.

Hettiarachchi R.J. , Lok J. , Prins M.H. . Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer. 1998; 4: 180–185.

Buller H.R. . Has time come for screening for occult cancer in patients with venous thromboembolism? J Thromb Haemost. 2004; 4: 874–875.